Empyema following the percutaneous instillation of antifungal agents in patients with aspergillosis.
We report two cases of empyema as a complication of the percutaneous instillation of antifungal drugs for pulmonary and pleural aspergillosis. Case 1 underwent percutaneous administration of amphotericin B and fluconazole for 2 months. Six months later, the patient was found to have an Aspergillus empyema with a bronchopleural fistula. Case 2 with pulmonary and pleural aspergillosis underwent percutaneous administration of amphotericin B for one month. Four months later, the patient underwent pleural drainage due to empyema. Pleural biopsy revealed pleural aspergillosis. In both cases, it was suggested that the preceding Aspergillus infection and percutaneous instillation of antifungals resulted in the development of empyema.
Nakanishi
Y
Y
Research Institute for Diseases of the Chest, Faculty of Medicine, Kyushu University, Fukuoka.
Wakamatsu
K
K
Nomoto
Y
Y
Kawasaki
M
M
Takayama
K
K
Yatsunami
J
J
Tsuruta
N
N
Hashimoto
S
S
Hara
N
N
D000368:Aged; D000666:Amphotericin B / Q000008:administration & dosage / Q000009:adverse effects; D000935:Antifungal Agents / Q000008:administration & dosage* / Q000009:adverse effects*; D001228:Aspergillosis / Q000150:complications / Q000188:drug therapy*; D004653:Empyema / Q000209:etiology*; D015725:Fluconazole / Q000008:administration & dosage / Q000009:adverse effects; D006801:Humans; D007267:Injections; D008172:Lung Diseases, Fungal / Q000150:complications / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D010995:Pleural Diseases / Q000150:complications / Q000188:drug therapy
D000935:Antifungal Agents; D000666:Amphotericin B; D015725:Fluconazole